European Pharmaceutical Review

OCTOBER 3, 2024

The post <em>European Pharmaceutical Review </em> Issue 4 2024 appeared first on European Pharmaceutical Review. Preparing for the impact of EU GMP Annex 1 on primary packaging Niamh Bissett and Dr Ana Kuschel West Pharmaceutical Services, Inc. Login or create an account to download your copy of our Issue now!

Packaging 59

Packaging Vaccines 59

Drug Channels

SEPTEMBER 11, 2024

Below, I review the latest data on 2024 trends and compare them to the pre-pandemic figures. For 2024, payers report that specialty pharmacies—via white and clear bagging—have displaced buy-and-bill for a meaningful share of commercial covered lives utilizing provider-administered oncology drugs.

Specialty Pharmacies 52

Specialty Pharmacies Hospitals 52

European Pharmaceutical Review

JULY 5, 2024

Following the Labour Party’s win yesterday in the UK 2024 General Election, industry representatives have voiced their opinions on what this could mean for the future of the pharmaceutical industry under the new government. EU pharmacovigilance is stronger with the UK, and UK research is stronger with the EU.”

Pharmaceutical Manufacturing 98

Pharmaceutical Manufacturing Vaccines 98

European Pharmaceutical Review

APRIL 29, 2024

The post Guide to Testing 2024 appeared first on European Pharmaceutical Review. BET sustainability from your endotoxin experts Associates of Cape Cod International showcases its services and its endotoxin testing capabilities. Interested? Register your details to download a copy.

52

52

ALiEM - Pharm Pearls

FEBRUARY 28, 2024

This blog post provides an update to our 2018 blog articles to reflect these changes. Accessed February 20, 2024. February 2024. Accessed February 20, 2024. Updated February 2024. Brief Description for: Article Title. Accessed February 20, 2024. Accessed February 20, 2024. Article Title.

130

130

Fuld & Company Blog

NOVEMBER 5, 2024

As deal activity marginally improved in Q3 2024, the global private equity trend finally seems to be turning the corner. The technology sector continues to dominate deal activity, accounting for 40% of the private equity deals in Q3 2024 – up from 31% in Q1.

52

52

European Pharmaceutical Review

MARCH 1, 2024

This Issue was brought to you in partnership with Fujifilm Irvine Scientific: The post <em>European Pharmaceutical Review </em> Issue 1 2024 appeared first on European Pharmaceutical Review.

64

64

Fuld & Company Blog

AUGUST 28, 2024

Insights at your fingertips Fuld’s US M&A dashboard is a quick yet comprehensive update on the US M&A landscape for H1 2024. What’s inside H1 2024 activity overview: A summary of the major shifts in M&A activity U.S.

52

52

The Thyroid Pharmacist

DECEMBER 29, 2023

My books, articles, supplements, and documentary were in the world for all to find and discover, so I cut back from media and publicity efforts for a few years while I enjoyed mama life. I also released a brand new program focused on gut health, as well as some more helpful articles this year. I am hoping to feel more settled in 2024.

Adverse Reactions 63

Adverse Reactions Immunity Immunization Diabetes 63

Digital Pharmacist

AUGUST 21, 2023

As we gear up for the upcoming flu season of 2023-2024, it’s important to reflect on the lessons of the previous year , and understand how the coming year may look different. 2023 Flu Vaccination Changes As we look at the 2023-2024 flu season, what’s new for this year? According to the CDC, in the 2023-2024 season, the U.S.

Vaccines 98

Vaccines Communication Immunity Immunization 98

Digital Pharmacist

SEPTEMBER 20, 2023

The Medicare Open Enrollment period for 2024 is quickly approaching – this is a critical time for both your patients and your pharmacy. Below is a breakdown of what you need to be aware of when assisting patients with 2024 open enrollments, as well as a few tips on how your pharmacy can prepare for this busy time at the pharmacy.

Independent Pharmacies 105

Independent Pharmacies Nursing Homes Immunity Immunization 105

Fuld & Company Blog

JANUARY 17, 2024

To kick off the New Year, I’d like to share with you some recent client success stories, as well as new ideas for driving revenue and increasing your competitive edge in 2024. In the first article, we share how Fuld recently helped a Private Equity firm increase revenues by 130% by identifying 300 targets in a niche industry.

52

52

European Pharmaceutical Review

JUNE 28, 2024

Articles included in Issue 3 of European Pharmaceutical Review include: FOREWORD Seeking perfection in an imperfect world Dave Elder David P Elder Consultancy REGULATORY INSIGHT Botanical drugs – what is the best way forward for regulatory and market approval?

Research Laboratories 52

Research Laboratories Vaccines Drug Development Immunity 52

Drug Channels

JANUARY 23, 2024

In a previous article , I highlighted the largest pharmacy chains that will participate in the 2024 Medicare Part D prescription drug plans (PDP). As you will see below, the largest PSAOs have effectively abandoned PDP’s preferred networks in 2024. Look out below! All rights reserved.

Independent Pharmacies 64

Independent Pharmacies 64

Drug Channels

OCTOBER 24, 2023

Open enrollment is under way for the 2024 Medicare Part D plans. For 2024: 94% of stand-alone Medicare Part D prescription drug plans (PDP) will have a preferred network. Below, I provide historical data on preferred networks’ growth and update the seven top companies’ 2024 offerings.

Independent Pharmacies 52

Independent Pharmacies 52

Drug Channels

APRIL 29, 2024

on how Medicare Part D plans will react to the Inflation Reduction Act Walgreens' unexpected specialty pharmacy strength A video deconstruction of my infamous Drug Channels article on GoodRx Plus, a cartoonist illustrates my recent keynote on the battle for oncology margin. All rights reserved.

Specialty Pharmacies 83

Specialty Pharmacies Biosimilars 83

ALiEM - Pharm Pearls

MAY 6, 2024

Launching the 2nd edition of Bridge to EM (2024) We are thrilled to announce that we launching the second edition of the curriculum. We also include a broader representation of foundational learning content such as the interpretation of diagnostic imaging as well as professional competency skills (e.g., communication, efficiency).

Communication 189

Communication 189

Drug Channels

APRIL 5, 2024

One important update: In the article below, I suggested that the IRA will make high-list/high-rebate products less attractive to Medicare plans. Click here to see the original post from January 2024. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. drug pricing.

Drug Pricing 68

Drug Pricing 68

Pharma Mirror

JANUARY 19, 2024

As we step into 2024, the global life science industry finds itself at a crossroads, facing plenty of challenges alongside an abundance of exciting opportunities. The pharmaceutical and contract outsourcing space has shifted, with new trends emerging that will shape the future of this rapidly changing industry.

Vaccines 52

Vaccines 52

Drug Channels

JULY 30, 2024

Go for a swim to cool off and then enjoy this refreshing selection of articles chosen by Drug Channels para tu. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Did the FTC’s compelling interim report prove its case? Attendance will be highly limited, so apply now. All rights reserved.

Biosimilars 40

Biosimilars Hospitals 40

European Pharmaceutical Review

JUNE 27, 2024

In a recent EPR article , investigator on the FRESCO-2 trial, Dr Sebastian Stintzing, highlighted that “with the good toxicity profile of fruqintinib [and] the easy oral administration [in the future we could] see…combinations of fruquintinib, plus either chemotherapeutic substances, target treatment options [or] immunoncology”.

Chemotherapy 64

Chemotherapy 64

Proxsys Rx

JANUARY 12, 2024

And that is why the one 340B prediction we can make for 2024, unequivocally, is repeated three times in this post’s headline. Which means we may see a lot more states putting manufacturers in their place, in 2024. How covered entities should prepare for 340B changes in 2024 Build a qualified 340B team.

Specialty Pharmacies 52

Specialty Pharmacies Hospitals Drug Pricing Packaging 52

Proxsys Rx

APRIL 19, 2024

And that is why the one 340B prediction we can make for 2024, unequivocally, is repeated three times in this post’s headline. Which means we may see a lot more states putting manufacturers in their place, in 2024. How covered entities should prepare for 340B changes in 2024 Build a qualified 340B team.

Specialty Pharmacies 52

Specialty Pharmacies Hospitals Drug Pricing Packaging 52

PharmaTech

MAY 12, 2024

This article considers technical and commercial best practices that drug developers may enact so that they, their suppliers and media manufacturers, and in turn, their cell culture media remain on the most efficient path to market. The importance of successfully scaling up cell culture media cannot be overstated.

Drug Development 52

Drug Development 52

Med Ed 101

SEPTEMBER 18, 2024

In this article, we will highlight some of the differences and similarities between Neffy and Epipen. Neffy was approved for patients who weigh over 30 kg or more by the FDA in August of 2024. […] The post Neffy Versus EpiPen – Clinical Comparison appeared first on Med Ed 101.

52

52

ID Stewardship

OCTOBER 14, 2024

In this article an infectious diseases pharmacist discusses something cool and something lame with 5 antibiotics. BCPS, BCIDP Article Posted October 2024, First Released in the August 2024 IDstewardship Newsletter 1. Authored By: Timothy P. Gauthier, Pharm.D.,

52

52

FDA Law Blog: Biosimilars

OCTOBER 16, 2023

Gonzalez — The Wall Street Journal (WSJ) recently published a series of articles as part of its special report “What’s Ahead for Artificial Intelligence.” Three of these articles focus on medical applications of Artificial Intelligence and Machine Learning (AI/ML) and explore FDA’s role in regulating such products.

Documentation 117

Documentation 117

Drug Channels

OCTOBER 3, 2024

This week, I’m rerunning some popular posts while we put the finishing touches on DCI’s new 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. The article below highlights an underappreciated consequence of the Inflation Reduction Act’s inflation rebates for Medicare Part B drugs. All rights reserved.

Documentation 52

Documentation 52

ID Stewardship

OCTOBER 14, 2024

In this article a pharmacist with experience in writing and publishing provides 5 quick tips for pharmacy residents preparing manuscripts Authored By: Timothy P. BCPS, BCIDP Article Posted October 2024, First Released in the June 2024 IDstewardship Newsletter Tip 1: Start by picking an article type and journal The article type (e.g.,

Documentation 52

Documentation Communication 52

ID Stewardship

OCTOBER 14, 2024

In this article an infectious diseases pharmacist discusses 5 neat things from the world of antimicrobials – let’s get nerdy! BCPS, BCIDP Article Posted October 2024, First Released in the September 2024 IDstewardship Newsletter 1. Authored By: Timothy P. Gauthier, Pharm.D., Read more here ([link].

52

52

ID Stewardship

OCTOBER 14, 2024

In this article an infectious diseases pharmacist with 20+ years of experience in the profession discusses 5 quick things to know about drug shortages. BCPS, BCIDP Article Posted October 2024, First Released in the July 2024 IDstewardship Newsletter 1. Authored By: Timothy P. Gauthier, Pharm.D.,

Communication 52

Communication 52

Drug Channels

AUGUST 13, 2024

Consider this article to be an opportunity for some fact-based analysis to replace your schadenfreude. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Drug Channels has been tracking retail pharmacies’ economic and business challenges —and Rite Aid’s troubles—for many years.

64

64

European Pharmaceutical Review

OCTOBER 23, 2024

Donanemab was approved by the US Food and Drug Administration (FDA) as Kisunla (donanemab-azbt) in July 2024. This was followed by regulatory approval in Japan in September 2024. .” Results from the TRAILBLAZER-ALZ 2 study were published in the Journal of the American Medical Association (JAMA) in July 2023.

Hospitals 52

Hospitals Drug Development 52

PharmaTech

JANUARY 1, 2024

This article considers technical and commercial best practices that drug developers may enact so that they, their suppliers and media manufacturers, and in turn, their cell culture media remain on the most efficient path to market. The importance of successfully scaling up cell culture media cannot be overstated.

Drug Development 40

Drug Development 40

STAT

FEBRUARY 1, 2024

On 2024 guidance, Merck said it expects sales in the range of $62.7-$64.2 In 2024, as in 2023, the industry’s fate seems inextricable from interest rates. If you’ve made it to the end of this article, you might be interested in joining this  secret list for an upcoming biotech newsletter.

Drug Pricing 306

Drug Pricing Vaccines Communication Drug Development 306

European Pharmaceutical Review

AUGUST 3, 2023

EPC’s new Cannabis flower monograph The new monograph Cannabis flower (Cannabis flower, monograph 3028) will be available next year in January 2024 with publication of the supplement 11.5. The monograph will enter into force several months later, in July 2024. 1 July 2024).

Compounding 98

Compounding Pharmaceutical Companies Pharmaceutical Companies 98

Safe Biologics

AUGUST 27, 2024

A 2024 survey of 270 U.S. Read the article in GaBI Journal here. Data has shown, however, that these policies are strongly opposed by physicians who prescribe biologics. physicians shows the importance of maintaining the robust data requirements undergirding the interchangeable designation. policy here.

Biosimilars 100

Biosimilars 100